SYFOVRE Approved for Geographic Atrophy in Australia
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) has announced a groundbreaking achievement as the Therapeutic Goods Administration (TGA) in Australia has granted approval for SYFOVRE (pegcetacoplan). This innovative treatment is specifically aimed at adult patients suffering from geographic atrophy (GA) associated with age-related macular degeneration (AMD) where the fovea remains intact, and central vision is under duress due to GA lesion development. SYFOVRE stands out as the first and only approved remedy for GA in Australia.
Significance of the Approval for Patients
This historic approval marks a pivotal moment for over 75,000 Australians afflicted with GA, a leading cause of blindness worldwide. This irreversible condition is characterized by the progressive deterioration of retinal cells due to GA’s lesion growth, ultimately resulting in significant vision impairment that affects individuals' independence and quality of life.
Dr. Jeffrey Eisele, chief development officer at Apellis, expressed enthusiasm about this achievement, stating, "The approval of SYFOVRE marks a significant milestone for GA patients across Australia. For the first time, Australians with GA will have a treatment to slow the progression of this irreversible form of vision loss.” This statement underscores the hope instilled by the new treatment, reflecting a similar excitement seen in the treatment's success in the United States.
Insights from Eye Specialists
Professor Robyn Guymer, AM, a retina specialist and deputy director at the Centre for Eye Research Australia, shared her perspective, elaborating on the impact of GA: "As a retina specialist, I have seen how GA often takes away a person’s ability to read, drive, and even see faces of their loved ones. The approval of SYFOVRE is a historic moment full of hope for the Australian GA community, who have been waiting for a treatment.” Her insights highlight the personal struggles faced by many individuals suffering from this debilitating condition.
Scientific Evidence Supporting Approval
The approval is based on the promising results from the Phase 3 OAKS and DERBY studies conducted over 24 months, which demonstrated that both the monthly and every-other-month administration of SYFOVRE effectively slowed GA progression. Additionally, these studies indicated a generally well-tolerated safety profile for the treatment, which offers further reassurance to patients and healthcare providers.
The findings from these studies were officially published in The Lancet in late 2023, reinforcing the credibility of this treatment option.
About SYFOVRE and Apellis Pharmaceuticals
SYFOVRE (pegcetacoplan injection) has been developed as the first-ever therapy for geographic atrophy (GA). It operates by targeting the C3 protein and aims to offer comprehensive control over the complement cascade — a crucial component of the immune system's function. The treatment is already approved in both the United States and Australia, demonstrating Apellis's commitment to addressing serious medical needs.
Apellis Pharmaceuticals is not just a biopharmaceutical company; it represents an intersection of innovative science and compassionate patient care. The firm has introduced the first new class of complement medicine in the past 15 years and holds two approved medications targeting C3. The company believes that it has only scratched the surface of what can be achieved by continuing to explore the potential of targeting C3 across various serious diseases.
Contact Information
For media inquiries, please contact:
Media Contact: Lissa Pavluk
Email: media@apellis.com
Phone: 617.977.6764
Investor Contact: Meredith Kaya
Email: meredith.kaya@apellis.com
Phone: 617.599.8178
Frequently Asked Questions
What is SYFOVRE?
SYFOVRE (pegcetacoplan) is the first approved treatment for geographic atrophy in Australia, designed to slow disease progression.
Who does SYFOVRE treat?
It is intended for adult patients with geographic atrophy secondary to age-related macular degeneration.
How effective is SYFOVRE?
Clinical studies showed that SYFOVRE significantly slowed GA progression while maintaining a favorable safety profile.
Where is SYFOVRE approved?
SYFOVRE is currently approved in both the United States and Australia.
How can I find more information about Apellis?
Further information can be found by visiting the Apellis website or their official social media channels.
